{
    "symbol": "MRVI",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-08 20:13:05",
    "content": " As it relates to the certain other adjustments needed to get to our non-GAAP adjusted EBITDA range, our expectations for 2022 include interest expense between $22 million and $25 million; depreciation and amortization increasing to $30 million to $35 million to incorporate updated estimates for amortization tied to finalizing the MyChem purchase price accounting; equity-based compensation, which we show as a reconciling item from GAAP to non-GAAP EBITDA to be $15 million to $20 million; and as stated earlier, for 2022, we expect to invest an estimated $65 million to $75 million for capital expenditures, a vast majority tied to new facility expansion."
}